Clinical Trials Logo

Filter by:
NCT ID: NCT01181700 Completed - Pharmacokinetics Clinical Trials

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Start date: October 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the time course of PF-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.

NCT ID: NCT01177839 Completed - Intussusception Clinical Trials

Study to Assess the Incidence of Intussusception in Children < 2 Years of Age in Singapore

Start date: May 2002
Phase: N/A
Study type: Observational

This prospective study aims to estimate the incidence of intussusception among children < 2 years old through hospital-based surveillance in Singapore.

NCT ID: NCT01170663 Completed - Gastric Cancer Clinical Trials

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

RAINBOW
Start date: December 2010
Phase: Phase 3
Study type: Interventional

This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.

NCT ID: NCT01168791 Completed - Soft Tissue Sarcoma Clinical Trials

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma

PICASSO III
Start date: July 2010
Phase: Phase 3
Study type: Interventional

This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS).

NCT ID: NCT01166217 Completed - Healthy Clinical Trials

A Single Dose Study Of PF-04620110 In Healthy Subjects

Start date: July 2010
Phase: Phase 1
Study type: Interventional

PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the relative bioavailability of three different oral dose formulations of PF-04620110.

NCT ID: NCT01163760 Completed - Refractive Error Clinical Trials

Clinical Evaluation of Two Daily Disposable Contact Lenses

Start date: September 2007
Phase: N/A
Study type: Interventional

This study seeks to evaluate the clinical performance of two daily disposable contact lenses.

NCT ID: NCT01163240 Completed - Hepatitis B Clinical Trials

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

EPIC B
Start date: June 2009
Phase: N/A
Study type: Observational

The purpose of this study is to collect epidemiological data in children and adolescents with chronic hepatitis B(CHB), in particular data on the prevalence of HBeAg positive disease with associated ALT levels , active HBeAg negative disease and decompensated CHB in the pediatric population. Family history and history of HBV transmission is essential to assess the course of the disease and can be used to determine the best mode of treatment This information will be used to assist with the feasibility and design of studies for the Novartis clinical pediatric development program, as the current epidemiology of ediatric CHB is not accurately known in Western countries or the rest of the world making pediatric studies difficult to plan and conduct. This study forms part of the Novartis Pediatric Investigational Plan, a post marketing approval commitment to the EMEA Pediatric Committee.

NCT ID: NCT01160211 Completed - Neoplasms, Breast Clinical Trials

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Start date: May 5, 2011
Phase: Phase 3
Study type: Interventional

A study to compare the safety and efficacy of an aromatase inhibitor in combination with lapatinib, trastuzumab or both for the treatment of hormone receptor positive, HER2+ metastatic breast cancer (MBC).

NCT ID: NCT01159483 Completed - Healthy Volunteer Clinical Trials

First-in-Human Study of PF-04958242 in Healthy Volunteers

Start date: July 15, 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study will evaluate the safety and tolerability of single, escalating doses of PF-04958242 administered orally to healthy adult participants. This study will also evaluate the plasma pharmacokinetics (PK) of single doses of PF-04958242 after single escalating doses of PF-04958242 administered orally to healthy adult participants.

NCT ID: NCT01157364 Completed - Ocular Hypertension Clinical Trials

Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension

Start date: September 23, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension. At least 3 dose strengths will be evaluated based on internal data review of each cohort. The study was planned to be conducted in 2 stages. Stage 1 was an open-label and Stage 2 was planned to be masked; however only Stage 1 was conducted.